Biogen

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat

News

Novartis offers reimbursement options as EU backs costly SMA...

Novartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare childhood wasting disease spinal muscular atrophy (SMA),

News

Closeup of X-ray photography of human brain

FDA clears US trials of Green Valley's Alzheimer's drug

China’s Shanghai Green Valley Pharmaceuticals has clearance to begin a late stage clinical trial to support a US filing of its potential Alzheimer’s drug.

News

Shionogi and Tetra expand partnership ahead of Alzheimer's t...

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.

News

Pharma staff told to work at home as Biogen deals with coron...

The coronavirus has begun to affect day-to-day operations at pharma companies, with Biogen dealing with an outbreak linked to a management meeting at an affected hotel, and others telling s

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Biogen and Sangamo work on Parkinson's and Alzheimer's gene ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 bi

After Celgene deal, BMS shoots up pharma market cap rankings

Novartis offers reimbursement options as EU backs costly SMA...

FDA clears US trials of Green Valley's Alzheimer's drug

Shionogi and Tetra expand partnership ahead of Alzheimer's t...

Pharma staff told to work at home as Biogen deals with coron...

Biogen and Sangamo work on Parkinson's and Alzheimer's gene ...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Biogen

Editor's Picks